TGTX
TG Therapeutics, Inc.

TG Therapeutics, Inc.TGTX

Healthcare · Biotechnology
56.44USD
+3.01%
Oct 28, 2026
TGTX overview ready
Developer and commercializer of B-cell targeted therapies for autoimmune diseases
TG Therapeutics is a commercial-stage, MS-focused biopharmaceutical company whose principal business is BRIUMVI, an intravenous anti-CD20 B-cell-depleting therapy for adults with relapsing forms of multiple sclerosis.
Narrative is still early
Exposed to the High-Efficacy Multiple Sclerosis Treatment Evolution narrative through Anti-CD20 B-Cell Therapies for Relapsing Multiple Sclerosis — pure play.
No clear price read
Longer-term context reads mature trend, with a near-term setup of daily advance.
Demanding valuation
The price embeds expectations that run ahead of what comparable businesses command.
Fundamentals under pressure
Free cash flow yield is weak.
Primary risk
Regulatory approval and compliance risks.
Market Oct 27Price action Oct 23Research Oct 23

Conviction Level

CompanyFit8.0PriceAction6.3Valuation0.3CompanyPosition7.3BusinessQuality—

Conviction uses Company Fit, Price Action, Valuation, Business Quality. Company Position is research context, not an input.

Theme leadershipGroup context · not a Conviction input
vs SPY
−3.6pp
Theme return
−3.1%
Beating SPY
6 of 21
21 sessions to Oct 27, 2026 · ranked 30 of 59 themes
Price
Loading price history…

Price Action

No clear price read
Longer-term context reads mature trend, with a near-term setup of daily advance.
EntryReset + recovery

The stock remains extended from its long-term weekly base, but the recent reset toward the daily SMA100 aligned with support at the weekly EMA21. Daily structure is recovering above the fast averages, improving the current entry location.

Key Financials

Market Cap
$8.3B
Avg Volume (60D)
1.7M
60 sessions
Revenue Growth YoY
+76.1%
Trailing twelve months
Gross Margin
+82.4%
Operating Margin
+17.1%
Trailing twelve months
Free Cash Flow Yield
+0.7%
P/E
19.7x
EV / EBITDA
62.3x
EV / Sales
10.6x
Market metrics as of Oct 27, 2026

Fundamentals & Valuation

One of the two valuation perspectives says expensive; intrinsic is the dissenting view.
This company has an Expensive valuation stance because the price embeds expectations that run ahead of what comparable businesses command. It trades at a 0.7% free-cash-flow yield and 62.3x EBITDA, which require sustained delivery to be justified.

Company Research

Thesis
TG Therapeutics is a commercial-stage, MS-focused biopharmaceutical company whose principal business is BRIUMVI, an intravenous anti-CD20 B-cell-depleting therapy for adults with relapsing forms of multiple sclerosis.
Opportunity
Moderate opportunity
Commercial adoption and regimen innovation for high-efficacy B-cell-depleting therapies in relapsing multiple sclerosis, including competition on efficacy, infusion or injection convenience, site of care, and payer access.
Key risk
Regulatory approval and compliance risks.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Biotechnology
What they do

TG Therapeutics develops, acquires, and commercializes novel treatments for B-cell mediated diseases, operating primarily in the United States and internationally.

How it earns

The company generates revenue through the commercial sale of its pharmaceutical products.

Products & services
BRIUMVI (anti-CD20 monoclonal antibody for relapsing multiple sclerosis)
Ublituximab IV (glycoengineered anti-CD20 monoclonal antibody in development)
Customers & end markets
Healthcare providers
Patients with B-cell mediated diseases, including multiple sclerosis
Market position

Niche player focused on B-cell targeted therapies within the biotechnology sector.

Demand drivers
Low cyclicality

Demand for treatments of chronic diseases like multiple sclerosis is relatively stable and less sensitive to economic cycles.